Zenas BioPharma, Inc. (ZBIO) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-02-13

Key Insights

The reporting person, Patricia L. Allen, a director of Zenas BioPharma, Inc. (ZBIO), has made multiple open market purchases of the company's common stock totaling 19,860 shares over the past two days.
The purchases were made at prices ranging from $23.77 to $26.50 per share, suggesting the director's confidence in the company's prospects.
The substantial insider buying activity may indicate the director's belief in the company's future growth and potential upside for shareholders.

Want the newest filings?

This analysis covers the filing from 2026-02-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-13

Hongbo Lu, a director of Zenas BioPharma, Inc., purchased 25,985 shares of the company's common stock at $22.5 per share on February 11, 2026.
The reported securities are owned indirectly by investment funds managed by NEXTBio Capital, and Hongbo Lu is a managing member of the general partners of these funds.
Insider buying can be a positive signal about the company's prospects, as the director is demonstrating confidence in the stock through their personal investment.

Other reports for Zenas BioPharma, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.